Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: In vitro Diagnostic Clear all

Conditions: Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
Interventions: Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152, Prednisone, PET, EKG, ECHO, CT neck chest, abdomen, and pelvis, MRI, Bone marrow aspiration/Biopsy; Device · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide Phosphate, Filgrastim, Fludarabine Phosphate, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Leucovorin Calcium, Melphalan, Mercaptopurine, Methotrexate, Pegfilgrastim, Pharmacological Study, Tacrolimus, Vincristine Sulfate; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 101
States / cities: Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more

Conditions: Aneuploidy, Down Syndrome, Noninvasive Prenatal Screening
Interventions: SEQureDx Trisomy Test; Device
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 3,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 27
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more

Conditions: Respiratory Syncytial Virus
Interventions: In Vitro Diagnostic device to aid in diagnosis; Device
Lead sponsor: Quidel Corporation; Industry
Eligibility: Up to 18 Years
Enrollment: 2,468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 17
States / cities: Phoenix, Arizona • Panorama City, California • Boynton Beach, Florida + 11 more

Conditions: Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Lesions Located at the Body or the Tail
Interventions: ARTIDIS ART-1 Device; Device
Lead sponsor: ARTIDIS AG; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Nanomechanical Phenotype Test; Diagnostic Test
Lead sponsor: ARTIDIS AG; Industry
Eligibility: 18 Years and older
Enrollment: 2,706 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • Seattle, Washington

Conditions: Plasma Cell Disorder
Interventions: IUO Plasma Cell Disorders Panel; Diagnostic Test
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: 22 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chlamydia Infections, Gonorrhea, Trichomonas Infections
Interventions: APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays; Device
Lead sponsor: Gen-Probe, Incorporated; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,336 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 14
States / cities: Birmingham, Alabama • San Diego, California • North Miami, Florida + 11 more

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Genetic + 3 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 45 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Lyme Disease
Interventions: T2Lyme Panel testing; Device
Lead sponsor: T2 Biosystems; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Wakefield, Rhode Island • La Crosse, Wisconsin

Conditions: Acute Infection
Interventions: MeMed BV; Diagnostic Test
Lead sponsor: MeMed Diagnostics Ltd.; Industry
Eligibility: 90 Days and older
Enrollment: 1,384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 5 more

Conditions: Breast Neoplasms, Breast Diseases
Interventions: OSNA Breast Cancer System; Device
Lead sponsor: Sysmex America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 11
States / cities: Santa Monica, California • Marietta, Georgia • St Louis, Missouri + 8 more

Conditions: Breast Cancer
Interventions: GeneSearch™ Breast Lymph Node (BLN) Assay; Device
Lead sponsor: Janssen Diagnostics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Craniosynostosis
Interventions: biopsy; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 2 Months to 18 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: COVID-19 Pandemic
Interventions: In Vitro; Diagnostic Test
Lead sponsor: 3EO Health; Industry
Eligibility: 2 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 5
States / cities: Gainesville, Florida • Miami, Florida • Sunrise, Florida + 2 more

Conditions: Diabetes, Hypertension
Interventions: ACR LAB; Device
Lead sponsor: Healthy.io Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 3
States / cities: Atlanta, Georgia • Lexington, Kentucky • Garden City, New York

Conditions: Bacterial Vaginosis, Candida Vaginitis
Interventions: cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP, Hologic Aptima BV Assay; Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 738 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Lakewood, Colorado + 5 more

Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
Interventions: Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies; Behavioral · Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 22 Years to 65 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
Interventions: Not listed
Lead sponsor: IQuum, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Delray Beach, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more

Conditions: Leukemia
Interventions: aldesleukin, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, in vitro treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 2 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Ulcerative Colitis
Interventions: UCRI; Diagnostic Test
Lead sponsor: Glycominds, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Infertility, Female, Endometriosis
Interventions: Endometrial Biopsy, Euploid embryo transfer, Blood sample; Procedure · Other · Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Sunnyvale, California

Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx); Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 40
States / cities: Daphne, Alabama • Greenbrae, California • Harbor City, California + 34 more

Conditions: Acute Coronary Syndrome, Myocardial Infarction
Interventions: Elecsys® Troponin T hs Gen 6, Blood sample collection; Diagnostic Test · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 20 Years and older
Enrollment: 5,429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 26
States / cities: El Centro, California • La Jolla, California • Gainesville, Florida + 21 more

Search by objective public record fields.

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies

Sofia RSV FIA Field Study

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer

Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel

Establish MeMed BV™ Performance for Differentiating Bacterial From Viral Infection in Suspected Acute Infection Patients (APOLLO STUDY)

Clinical Evaluation of OSNA Breast Cancer System to Test Sentinel Lymph Nodes From Patients With Breast Cancer

Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer

Osteogenic Profiling of Tissue From Children With Craniosynostosis

SARS-CoV-2 OTC At Home Test

ACR | LAB Urine Analysis Test System Evaluation of Performance

Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

The Liver Health Study for Patients with NAFLD

Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer

Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI Biomarker Panel and Algorithm to Detect Mucosal Healing in Moderate to Severe Ulcerative Colitis Patients.

Predicting Endometrial Receptivity for Optimal Reproductive Management

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome